Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis
- If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
- Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
- Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso